HOME2019-03-11T17:27:49+01:00

The PD-MitoQUANT Project

Today, more than one million people live with Parkinson’s in Europe and this number is forecast to double by 2030. New, more effective treatments are urgently needed – but researchers and companies developing new drugs need to know more about how mitochondrial dysfunction is involved in disease progression and better models are needed for drug discovery and development.

PD-MitoQUANT is an Innovative Medicines Initiative (IMI) project that brings together academic experts, SMEs, pharmaceutical companies from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and patient advocacy organisation Parkinson’s UK to:

  • improve our understanding of mitochondrial dysfunction in Parkinson’s,

  • identify and validate molecular drivers and mechanisms in Parkinson’s, and

  • discover innovative therapeutic targets that can be further progressed by the EFPIA partners in the future.

Latest News

PD-MitoQUANT PIs at CNRS co-author review in the Journal of Neurochemistry

August 20th, 2019|

A review was recently published in the Journal of Neurochemistry which acknowledged PD-MitoQUANT research funding. "α‐synuclein oligomers and fibrils: a spectrum of species, a spectrum of toxicities" authored by a team consisting of Parvez Alam, Luc Bousset, Ronald Melki and Daniel E. Otzen appeared in the 29 June 2019 issue. Ronald [...]

Check out our first newsletter!

August 8th, 2019|

It's hard to believe we're halfway through our first year! Learn more about the team and the project in our first newsletter...

Interview with PD-MitoQUANT PI Prof Dr Dino Di Monte, DZNE

June 20th, 2019|

A few questions were posed to PI Prof Dr Donato (Dino) DiMonte to gain his views on his work in Parkinson research and PD-MitoQUANT, in general. Dino is a senior researcher and leads the Neurodegeneration and Neuroprotection in Parkinson’s Disease Group at the German Center for Neurodegenerative Diseases (DZNE). Please [...]

Read more